Connecta Therapeutics is a biotechnology company – created as a spin-off from Prous Institute for Biomedical Research – which develops new treatments for CNS unmet medical needs.
The company will initially focus on the clinical development of a new "first-in-class" molecule, JRP655, for the treatment of fragile X syndrome (FXS). FXS is the most common cause of hereditary intellectual disability and there are no therapeutic interventions currently available.
JRP655 was discovered by Prous Institute for Biomedical Research after evaluating more than 30 molecular and cellular targets. The molecule has been proven, in in vitro tests and in vivo in animal models, to be an excellent neuroplasticity modulator with a great extension profile for other neurodevelopmental disorders (Rett syndrome, Down syndrome and autism spectrum disorders, among others).
About Prous Institute for Biomedical Research
Prous Institute for Biomedical Research is a private research organization based in Barcelona, born as a spin-off from Prous Science, leading provider of scientific information (Drugs of the Future, Drug Data Report and the Integrity drug discovery and development portal, among others) which was acquired by Thomson Reuters in 2007.
Main sector: Medic biotechnology